Clinical Trials Browser

Biliary Tract Neoplasms × pembrolizumab × 1 year × Clear all

NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05849480 2026-02-05

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Phase 1/2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms

NCT06428409 2026-01-22

MK-9999-02A

Phase 1/2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT05998447 2025-12-16

GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Phase 2 Terminated

Gastrointestinal

Biliary Tract Neoplasms

NCT07269158 2025-12-08

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06001658 2025-12-03

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma

NCT03797326 2025-11-17

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

Phase 2 Active not recruiting

1,609 enrolled 5 FDA

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT06178445 2025-08-19

TRAP-BTC

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05784688 2025-03-30

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Colorectal Neoplasms